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Introduction
Cognitive function declines with ageing, especially cognitive domains related to memory and information processing speed. 1 Changes in cognitive performance, especially memory function, have been linked to risk of dementia in old age. 2, 3 Modifi able risk factors for agerelated cognitive decline have been identifi ed, but their causality has not yet been established. 4 Poor folate status is one such suspected risk factor. 5, 6 A longitudinal study, 7 undertaken in the USA when folic acid fortifi cation of foods was routine, showed greater cognitive decline in people with a high folic acid intake than in those with low intakes. A systematic review of supplementation with folic acid alone or in combination with other B vitamins showed that no benefi cial eff ect on cognitive performance was conferred. 8 Many of the trials have used small study populations, supplemented for a short duration, or used tests such as the Mini-Mental State Examination, 9 which are unable to detect subtle changes in cognitive function (table 1). [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] We investigated whether 800 µg daily oral folic acid supplementation for 3 years improved cognitive performance compared with placebo in older adults. Cognitive performance was assessed with tests that probe cognitive domains that decline in the ageing process.
Methods

Participants
Participants were men and post-menopausal women aged 50-70 years, from the Gelderland region in the Netherlands who participated in the Folic Acid and Carotid Intimamedia Thickness (FACIT) trial (unpublished), a study investigating the eff ect of folic acid supplementation on atherosclerotic progression. Additional outcomes of the trial were age-related decline in cognitive function and hearing. Here we present data for the eff ect of folic acid on the cognitive performance aspect of the study.
We used municipal and blood-bank registries to recruit participants. On the assumption that high concentrations of plasma total homocysteine were a risk factor for vascular disease, we selected participants expected to benefi t from folic acid's homocysteine-lowering eff ect and excluded participants with concentrations of plasma total homocysteine of less than 13 μmol/L (73% of those screened). We excluded participants with raised homocysteine concentrations (>26 µmol/L) that were possibly due to factors other than suboptimal folate concentrations, including: serum vitamin B 12 concentration of less than 200 pmol/L (10% of those screened); selfreported medical diagnosis of renal or thyroid disease; or self-reported use of medications that infl uence folate metabolism. 20 Additionally, we excluded participants with self-reported intestinal disease and participants who reportedly used B-vitamin supplements or drugs that could aff ect atherosclerotic progression. Finally, more than 80% self-reported compliance during a 6-week placebo run-in period was required. The Wageningen University medical ethics committee approved the study and participants gave written informed consent.
Procedures
After the initial measurement sessions, participants were allocated placebo or 800 µg per day folic acid, which is regarded as a low dose for a clinical trial. Patients were allocated treatment or placebo with permuted blocks of sizes four and six, which varied randomly. Specialised staff who were not involved in the study allocated and labelled the capsule boxes with participants' unique sequence number. Participants in the same household received the same treatment. The folic acid and placebo capsules, produced by Swiss-Caps Benelux (Heerhugowaard, Netherlands), were indistinguishable in appearance. Capsules were individually packaged in foil strips containing 28 capsules per strip, with the days of the week printed on the back. Every year, participants received a 13-month supply of capsules. Compliance was judged by capsule-return counts and a diary that registered missed capsules. Diaries and capsules were returned by participants every 12 weeks.
At the end of the study, the proportion of participants who thought they had received folic acid or placebo did not diff er between the two groups (p=0·64). 70% of participants in the folic acid group and 71% in the placebo group thought they had been allocated folic acid; whereas 11% in the folic acid group and 9% in the placebo group thought they had been allocated placebo. All staff , including all authors, were unaware of group assignment until completion of the trial and after data analyses. We assessed cognitive function using fi ve separate tests used in the Maastricht Aging Study. 21 These fi ve tests were used to construct fi ve a-priori-defi ned cognitive domains: memory, sensorimotor speed, complex speed, information processing speed, and word fl uency. 22 Descriptions of the tests are in panel 1. [23] [24] [25] [26] [27] Although not part of the cognitive tests used for our study outcome, we used the Mini-Mental State Examination 9 to screen for participants with possible dementia, defi ned as a score of less than 24 points.
All participants underwent the measurements after an overnight fast, followed by a glass of fruit juice and a bread product for breakfast. Two trained research assistants oversaw the tests during a 40-min session; they used standard wording to instruct participants. A third research assistant periodically observed the testing to ensure that the two research assistants did not deviate from the protocol. All cognitive tests were done in the same room with the same props. We repeated cognitive testing at the end of the study using variations of the tests used at baseline (parallel versions). We repeated the verbal fl uency test because the validity of a parallel version of the animalnaming part of the test has not been established.
Fasting venous blood was processed and samples were stored at 80ºC. We measured serum folate, erythrocyte folate, serum vitamin B 12 , plasma total homocysteine, plasma vitamin B 6 , serum creatinine, and lipids as described elsewhere. 22 The C677T polymorphism in the gene encoding methylenetrahydrofolate reductase (MTHFR) 28 and apolipoprotein E genotype were determined by PCR of DNA and restriction digestion with HinFl and Hha1, respectively.
Self-reported medical history, including current drug use and smoking habits, were ascertained by questionnaire (Continued from previous page) Bryan et al 15 
Table : Summary of randomised controlled trials examining eff ect of folic-acid-containing supplements on cognitive function
and reviewed by a research assistant with the participant. Education was grouped according to highest attained level. 29 Height and weight were measured and body-mass index calculated. Blood pressure was measured with an automated meter (Dinamap Compact Pro 100, General Electric). Eight blood-pressure measurements were taken and the average calculated. We used a food-frequency questionnaire to estimate dietary folate intake during the past 3 months.
We measured genotype and attained educational level at the beginning of the study. Plasma total homocysteine, serum folate, and vitamin B 12 concentrations and information about medical status and drug use were recorded yearly and all other measurements were taken at the beginning and end of the study.
Statistical analyses
Our sample size calculation was based on the mean intimamedia thickness progression of the common carotid artery (the primary endpoint of the FACIT trial). We assumed that if the progression of the mean carotid intima-media were 0·01 mm (SD 0·06 mm), then 251 participants would be needed in each group to detect a diff erence of 0·015 mm (power 80%, two-sided α=0·05). We assumed that 30-40% of the population could be lost to follow-up.
The cognitive domains were constructed with Z scores (panel 2). 21 Sensorimotor speed measures basic speed, and shows direct stimulus-response connections with little central processing, whereas complex speed measures time needed for higher-order information processing. As other investigators have done, 30, 31 we present global cognitive function (an average of the domains). The test scores at the beginning and end of the study were pooled to calculate the grand mean and SD per test; this information was used to calculate the Z scores (panel 2). At baseline, one participant missed 50% or more of the subtests for complex speed and three participants did not have an information processing speed score. These participants were assigned the median score of these domains of the total population at baseline. 17 participants lost to followup were assigned the median test score of the total population at the end of the study. Analyses were done on an intention-to-treat basis with SPSS 11.0. No adjustments were made for multiple testing.
The outcome of this study was the diff erence between the folic acid and placebo groups in the 3-year change in performance for memory, sensorimotor speed, complex speed, information-processing speed, and word fl uency.
We used the t test to determine whether the change in cognitive performance diff ered between treatment groups. We did all analyses without knowledge of followup folate or homocysteine concentrations. The treatment code was broken once an independent statistician had verifi ed the data and all authors had formally approved the tables showing the main eff ects.
In secondary analyses, we determined whether the eff ect of folic acid supplementation was dependent on initial concentrations of folate or homocysteine or MTHFR C677T genotype. We determined the eff ect of folic acid
Panel : Description of cognitive function tests
Word learning test 23 Measures the storage and retrieval of newly acquired verbal information. Participants were instructed to memorise 15 commonly used monosyllabic words. The words were printed on a card and were presented in a fi xed sequence for 2 s. Immediately after the 15 words are presented, the participants are asked to recall the words. This procedure was done three times. 20 min after presentation of the words, participants were prompted to recall the 15 words. The maximum and total number of correctly repeated words of the immediate recall tests were recorded, as well as the number of correctly repeated words in the delayed recall test. 24 A timed test with four subtests that measure the ease of switching between two psychological concepts. Each subtest was printed on one sheet of paper, which contained 16 circles (15 mm diameter) arranged in a larger circle (16 cm diameter). For the fi rst subtest, participants were asked to cross off the circles in numerical and alphabetical order (eg, 1, A, 2, B, 3, C, etc). 25 Measures selective attention and susceptibility to behavioural interference and consists of three subtests. Each subtest was presented on a separate sheet containing four rows of ten columns of colour names of coloured blocks. For the fi rst subtest, participants were instructed to read words printed in black ink (words were "red", "blue", "green", and "yellow").
Concept shifting test
Stroop colour-word test
Participants were asked to name coloured blocks in the second subtest, for the fi nal subtest, participants were asked to name the colour of the ink, rather than read the word (eg, say blue when the word "RED" was printed in blue ink). 26 Measures word fl uency or the ability to draw on one's encyclopaedic memory in a strategic manner. Participants were asked to name as many animals as possible in 1 min. This test indicated the amount of organisation among clusters of related words (eg, pets, zoo animals, etc). 27 Assesses general speed of visual information processing. Nine diff erent letters were assigned a unique number (1) (2) (3) (4) (5) (6) (7) (8) (9) in a key at the top of the form. The participants were presented with a random series of letters in cells and were instructed to add the corresponding digit to the letters. The number of correctly copied corresponding digits in 90 s was recorded.
Verbal fl uency test
Letter digit substitution test
Panel : Construction of cognitive domains with Z-scores
Memory=(Z 15 supplementation per stratum (median cut-off ) using an independent sample t test. We used linear regression models to examine whether the diff erence in treatment eff ects between strata was signifi cant.
Role of the funding source
The sponsors had no role in the design or implementation of the study, data collection, data management, data analysis, data interpretation, or in the preparation, review, or approval of the manuscript. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Patients were randomised between November, 1999, and April, 2001, and the study was undertaken from September, 2000, to December, 2004. The fi gure shows the trial profi le. Five participants allocated folic acid treatment reported adverse events: forgetfulness, sun allergies, weight gain, tinnitus, and dark urine. Adverse eff ects reported in the placebo group (n=7) were muscle aches, headaches, weight gain, queasiness, bitter taste in mouth, and skin irritations.
The participant with headache complaints dropped out of the trial prematurely. 17 participants (2%) did not return for the cognitive function measurements after 3 years, and six participants stopped treatment prematurely. The proportion of participants lost to follow-up or who stopped treatment early did not diff er between the groups (p=0·25). Apart from these participants, the compliance of the participants was high, with 99% of the capsules reportedly consumed. Table 2 shows baseline clinical characteristics of the participants.
In both groups, plasma total homocysteine concentrations at baseline were lower than at screening, a likely result of regression to the mean (table 3) . After 3 years, serum folate concentrations were signifi cantly higher in the folic acid group than in the placebo group (table 3) .
Baseline scores on the cognitive tests and domains were similar between the two groups (table 4) . At baseline, one participant in the folic acid group and six in the placebo group scored less than 24 points on the Mini-Mental State Examination (p=0·85). Whereas sensori motor speed, information-processing speed, and complex speed declined signifi cantly during the 3-year study in the placebo group, the rate of decline was slower in these domains in the folic acid group (table 5) . Both groups improved on memory tests, because of procedural learning eff ects. However, the improvement was signifi cantly greater in the folic acid group than in the placebo group. The 3-year change in cognitive function was signifi cantly better in the folic acid group than in the placebo group in terms of information-processing speed. Folic acid did not aff ect sensorimotor speed, complex speed, or word fl uency. Global cognitive function, defi ned as the average of the fi ve domains, improved signifi cantly (table 5). Performance on the Mini-Mental State Exam ination was not aff ected by folic acid group (p=0·63). The median score for both groups after 3 years was 29 points (IQR 28-30) ranging from 21 to 30 points in the folic acid and 16 to 30 points in the placebo group.
In addition to memory and information-processing speed, sensorimotor speed improved signifi cantly (p<0·05) when other imputation techniques were used (eg, last value carried forward, expectation maximisation), when 17 participants lost to follow-up were excluded from the analyses, and when seven participants with initial Mini-Mental State Examination scores of less than 24 points were excluded from the analyses. Finally, at baseline, a greater proportion of participants with a low educational level, an important determinant of cognitive performance, were randomised into the folic acid group. Additionally, a higher proportion of participants in the folic acid group had dyslipidaemia and self-reported vascular disease. Our results did not change when we adjusted for these variables.
51 participants received the same treatment and lived in the same households. Hence these observations were not independent of one another. When partners were excluded from the analyses, the results did not change, except that folic acid supplementation signifi cantly improved sensorimotor speed (diff erence in Z scores 0·079 [95% CI 0·014-0·145]).
To show the relevance of our fi ndings we compared the regression coeffi cient of age-adjusted for sex, education, and treatment calculated with linear regression models with initial performance as the dependent variable-with the treatment eff ect. 3-year folic acid supplementation confers an individual the performance of someone 4·7 years younger for memory (95% CI 1·1-8·3), 1·7 years younger for sensorimotor speed (-0·04 to 3·4), 2·1 years younger for information processing speed (0·4-3·7), and 1·5 years younger for global cognitive function (0·1-2·8). Of our test battery, memory-specifi cally delayed memory-is the most clinically relevant test. We showed that 3-year folic acid supplementation improved performance on the delayed recall sub-test of the 15 word learning test by 0·47 words (95% CI 0·14-0·79, p=0·005). This improvement is similar to a performance of an individual 6·9 years younger (95% CI 2·1-11·8).
The eff ect of folic acid supplementation was not modifi ed by initial folate status or MTHFR C677T genotype.
Compared with placebo, participants with initial plasma total homocysteine concentrations greater than the population median of 12·9 µmol/L showed a greater improvement in information processing speed than participants with concentrations lower than the population median (interaction term p=0·034). Informationprocessing speed of the latter group improved by 0·013, (95% CI -0·086 to 0·111), whereas participants with higher homocysteine concentrations improved by 0·166, (0·064-0·267). Outcomes of the other four domains and global cognitive function were not aff ected by initial plasma total homocysteine concentrations.
In post-hoc analyses, we examined whether low concentrations of vitamin B12 modifi ed the eff ect of folic acid supplementation on cognitive performance. Folic acid supplementation improved sensorimotor speed (diff erence in Z score 0·112, 95% CI 0·001-0·223) and information processing speed (0·190, 0·055-0·325) in 230 participants with initial low or normal concentrations of vitamin B 12 (<250 pmol/L), but not in 588 participants with vitamin B 12 concentrations of 250 pmol/L or greater (0·046, -0·033 to 0·126 and 0·048, -0·036 to 0·131, respectively). 
Discussion
In 818 older adults, daily oral folic acid supplementation for 3 years benefi cially aff ected global cognitive function, and specifi cally memory, and information processing:
functions that are sensitive to ageing. 1 The decline in memory seen with ageing is generally preceded, and might be aff ected, by a decline in speed functions. 32 Nonetheless, folic acid supplementation might benefi cially aff ect both memory and speed simultaneously, since high concentrations of homocysteine have been associated with atrophy of the hippocampus, an area of the brain which is important for memory consolidation. 33 Complex speed, a domain sensitive to ageing, 1 was not aff ected by folic acid supplementation. The eff ect of folic acid might be restricted to basic aspects of speed and information processing, rather than high order information processing. Word fl uency was not aff ected by folic acid supplementation, perhaps not surprisingly, because encyclopaedic memory is a component of crystallised intelligence that stays relatively intact as one grows older. 34 Our study might have yielded demonstrable eff ects of folic acid on cognitive function because we used sensitive tests that exist in parallel versions. We also improved the robustness of the underlying cognitive constructs by clustering raw test scores for several tests in compound performance measures. This procedure decreased variation associated with the individual tests. Finally, clustering of raw tests scores limited our cognitive performance outcomes to fi ve a-priori defi ned outcomes.
By contrast with other trials, we were able to detect an eff ect of folic acid on several cognitive functions, for several reasons. First, assuming that high plasma total homocysteine concentrations are a causal risk factor for cognitive decline, we selected a population likely to benefi t from folic acid supplementation. Second, we had a fairly large study population and supplemented for quite a long period. Third, although we did not attempt to measure the prevalence of dementia at baseline nor its incidence during the duration of the trial, our population is unlikely to have included many cognitively impaired or demented participants, since the general performance on a dementia screening test such as the Mini-Mental State Examination was high, both at the beginning and end of the study. That treatment with folic acid or other B vitamins might feasibly be too late in populations with mild cognitive impairment and dementia. Finally, sensitive tests such as our own-not the commonly used Mini-Mental State Examination, which is a dementia screening device-were needed to detect the subtle eff ects of B vitamins on cognitive ageing. Importantly, given the general scarcity of positive fi ndings from other trials (table 1) and the multiple comparisons made in our trial, our results need to be confi rmed by other investigators to ascertain whether the signifi cant positive eff ects of folic acid on cognitive performance were due to type 1 error.
A strength of our study is the low attrition rate; a high attrition rate might have biased our fi ndings of cognitive change, since participants with poor cognitive function are likely to withdraw from studies. 35 In our study, the 12 participants in the folic acid group and fi ve participants in the placebo group who did not return for the end measurements had low scores only on baseline tests of memory (0·558 Z score, 95% CI 0·116-1·000). Their absence from year-3 tests is unlikely to have aff ected our estimates for several reasons: the eff ect of folic acid supplementation on memory was not dependent on baseline performance on the memory tests (data not shown), the number of participants lost to follow-up was minimal, and the eff ect estimates based on participants with follow-up data were similar to the intention-to-treat analyses. A second strength was the standardised test conditions that reduced variation due to factors such as caff eine and varying breakfasts. 36 Our study also had some limitations. First, we studied participants with high plasma total homocysteine concentrations: 3044 out of 4200 participants were excluded from the study because of low plasma total homocysteine concentrations. Thus, the eff ect of folic acid supplement ation on cognitive function might be greater than would be expected in populations with lower plasma total homo cysteine concentrations-eg, in countries such as the USA, with mandated fortifi cation of fl our with folic acid. Second, our fi ndings pertain only to vitamin B12-replete individuals. Suggestions have been made that folic acid supplemen tation exacerbates neurological symptoms in people with vitamin B 12 defi ciency. 37 The possibility of folic-acid-mediated exacerbation of neuropathological dis orders in people with low concentrations of vitamin B 12 needs to be addressed by studies that monitor both vitamin B 12 status and neurological function. As an improvement to our own study, transcobalamin in addition to vitamin B 12 , should be measured, because transcobalamin is a better marker of vitamin B 12 status than is vitamin B 12 itself.
Will folic acid supplementation lead to a reduced incidence of dementia? Whereas some have argued that cognitive decline is the beginning of a continuum leading to dementia, 38 others have argued that the cause of agerelated cognitive decline diff ers from that of dementia 39 and that age-related cognitive decline is not an early state of mild cognitive impairment or dementia. 2 Cognitive tests diff er in their ability to identify individuals who worsen to more advanced states such as mild cognitive impairment or dementia. Of our test battery, memory is the most clinically relevant domain. Memory can be used to distinguish between cognitively normal and cognitively impaired people. 2 Memory storage (delayed recall), in particular, can distinguish between people with nonprogressive mild cognitive impairment and preclinical Alzheimer's disease. 40 Although folic acid improved performance on tests of memory, including delayed recall, additional research is needed to determine whether folic acid supplementation can reduce the risk of mild cognitive impairment or Alzheimer's disease.
We have shown that 3-year folic acid supplementation improves performance on tests that measure informationprocessing speed and memory, domains that are known to decline with age, in older adults with raised total homocysteine concentrations. Randomised, controlled trials are underway to examine the eff ect of homocysteinelowering on recurrent vascular disease and cognitive function assessed by the Mini-Mental State Examination or modifi cations thereof; these and other homocysteinelowering trials should include sensitive measures of cognitive function. Additionally, trials similar to our own should be repeated in other populations to provide greater insight into the clinical relevance of folic acid supplementation, such as in populations with mild cognitive impairment and dementia.
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